8-K current report · filed Aug 5, 2026

Vaxcyte, Inc. (PCVX) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1PCVX overview

Short answer

Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.

Vaxcyte, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release issued August 5, 2026, with full results in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • VAX-31 adult Phase 3 fully enrolled with 6,191 participants, supporting pivotal OPUS-1 topline data expected in Q4 2026
  • OPUS-2 and OPUS-3 results expected in H1 2027, alongside manufacturing consistency work needed for planned BLA submission
  • Cash, cash equivalents and investments $2.508B as of June 30, 2026, supporting clinical, manufacturing and commercial-readiness spending
  • Q2 R&D expense $267.9M vs $194.2M, driven by VAX-31 trials, manufacturing preparation and expanded personnel
  • Q2 net loss $284.3M, or $1.97 per share, vs $166.6M, or $1.22 per share, reflecting sharply higher development spending

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vaxcyte, Inc. 8-K filings

Get the next PCVX 8-K as it lands

Follow PCVX for push alerts, or ask the research agent what this filing means.